Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
First-in-human intradermal administration of CoronaTcP™ was generally well-toleratedEvidence for generation of virus-specific effector and memory CD8+ T cellsData reinforce findings...
Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed